Douglas J. Loftus
About
In The Last Decade
Douglas J. Loftus
19 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 70
- Immunology 1.2k
- Molecular Biology 593
- Oncology 520
- Radiology, Nuclear Medicine and Imaging 152
- Genetics 104
Countries citing papers authored by Douglas J. Loftus
This map shows the geographic impact of Douglas J. Loftus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas J. Loftus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas J. Loftus more than expected).
Fields of papers citing papers by Douglas J. Loftus
This network shows the impact of papers produced by Douglas J. Loftus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas J. Loftus. The network helps show where Douglas J. Loftus may publish in the future.
Co-authorship network of co-authors of Douglas J. Loftus
This figure shows the co-authorship network connecting the top 25 collaborators of Douglas J. Loftus. A scholar is included among the top collaborators of Douglas J. Loftus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas J. Loftus. Douglas J. Loftus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 38 | |
| 3 | 51 | |
| 4 | 20 | |
| 5 | 4 | |
| 6 | A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. | 80 |
| 7 | 72 | |
| 8 | 95 | |
| 9 | 26 | |
| 10 | Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). | 59 |
| 11 | 33 | |
| 12 | Functional and structural issues related to epitope cross-recognition by T cells. | 1 |
| 13 | 438 | |
| 14 | 6 | |
| 15 | 204 | |
| 16 | 154 | |
| 17 | 66 | |
| 18 | 40 | |
| 19 | 3 | |
| 20 | 37 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.